BH.IMMUN&BIO | ADVANCED ENZYME TECHNOLOGIES | BH.IMMUN&BIO/ ADVANCED ENZYME TECHNOLOGIES |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -7.6 | 31.2 | - | View Chart |
P/BV | x | 1.5 | 3.5 | 42.9% | View Chart |
Dividend Yield | % | 0.0 | 1.3 | - |
BH.IMMUN&BIO ADVANCED ENZYME TECHNOLOGIES |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BH.IMMUN&BIO Mar-23 |
ADVANCED ENZYME TECHNOLOGIES Mar-23 |
BH.IMMUN&BIO/ ADVANCED ENZYME TECHNOLOGIES |
5-Yr Chart Click to enlarge
|
||
High | Rs | 52 | 328 | 15.8% | |
Low | Rs | 21 | 225 | 9.1% | |
Sales per share (Unadj.) | Rs | 10.3 | 48.3 | 21.4% | |
Earnings per share (Unadj.) | Rs | -3.9 | 9.3 | -41.5% | |
Cash flow per share (Unadj.) | Rs | -3.8 | 12.4 | -30.6% | |
Dividends per share (Unadj.) | Rs | 0 | 5.00 | 0.0% | |
Avg Dividend yield | % | 0 | 1.8 | 0.0% | |
Book value per share (Unadj.) | Rs | 20.4 | 110.5 | 18.5% | |
Shares outstanding (eoy) | m | 43.18 | 111.82 | 38.6% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.5 | 5.7 | 61.1% | |
Avg P/E ratio | x | -9.4 | 29.8 | -31.5% | |
P/CF ratio (eoy) | x | -9.5 | 22.3 | -42.6% | |
Price / Book Value ratio | x | 1.8 | 2.5 | 70.6% | |
Dividend payout | % | 0 | 53.8 | -0.0% | |
Avg Mkt Cap | Rs m | 1,561 | 30,939 | 5.0% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 151 | 1,148 | 13.2% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 446 | 5,406 | 8.3% | |
Other income | Rs m | 11 | 255 | 4.2% | |
Total revenues | Rs m | 457 | 5,661 | 8.1% | |
Gross profit | Rs m | -161 | 1,534 | -10.5% | |
Depreciation | Rs m | 2 | 350 | 0.6% | |
Interest | Rs m | 71 | 35 | 203.0% | |
Profit before tax | Rs m | -223 | 1,404 | -15.9% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | -56 | 365 | -15.4% | |
Profit after tax | Rs m | -166 | 1,039 | -16.0% | |
Gross profit margin | % | -36.0 | 28.4 | -126.9% | |
Effective tax rate | % | 25.3 | 26.0 | 97.2% | |
Net profit margin | % | -37.3 | 19.2 | -194.1% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 358 | 7,221 | 5.0% | |
Current liabilities | Rs m | 940 | 776 | 121.2% | |
Net working cap to sales | % | -130.6 | 119.2 | -109.5% | |
Current ratio | x | 0.4 | 9.3 | 4.1% | |
Inventory Days | Days | 85 | 255 | 33.5% | |
Debtors Days | Days | 1,135 | 68 | 1,676.0% | |
Net fixed assets | Rs m | 1,262 | 6,884 | 18.3% | |
Share capital | Rs m | 432 | 224 | 193.1% | |
"Free" reserves | Rs m | 450 | 12,127 | 3.7% | |
Net worth | Rs m | 882 | 12,351 | 7.1% | |
Long term debt | Rs m | 0 | 78 | 0.0% | |
Total assets | Rs m | 1,620 | 14,105 | 11.5% | |
Interest coverage | x | -2.2 | 41.4 | -5.2% | |
Debt to equity ratio | x | 0 | 0 | 0.0% | |
Sales to assets ratio | x | 0.3 | 0.4 | 71.8% | |
Return on assets | % | -5.9 | 7.6 | -77.7% | |
Return on equity | % | -18.9 | 8.4 | -224.3% | |
Return on capital | % | -17.2 | 11.6 | -148.9% | |
Exports to sales | % | 0 | 17.3 | 0.0% | |
Imports to sales | % | 14.5 | 7.8 | 186.2% | |
Exports (fob) | Rs m | NA | 937 | 0.0% | |
Imports (cif) | Rs m | 65 | 420 | 15.4% | |
Fx inflow | Rs m | 0 | 937 | 0.0% | |
Fx outflow | Rs m | 65 | 420 | 15.4% | |
Net fx | Rs m | -65 | 518 | -12.5% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 109 | 1,404 | 7.8% | |
From Investments | Rs m | 5 | -2,982 | -0.2% | |
From Financial Activity | Rs m | -147 | -258 | 57.0% | |
Net Cashflow | Rs m | -34 | -1,709 | 2.0% |
Indian Promoters | % | 59.3 | 2.4 | 2,448.3% | |
Foreign collaborators | % | 0.0 | 41.1 | - | |
Indian inst/Mut Fund | % | 0.0 | 30.6 | - | |
FIIs | % | 0.0 | 23.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 40.8 | 56.5 | 72.1% | |
Shareholders | 35,313 | 68,640 | 51.4% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare BH.IMMUN&BIO With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB ZYDUS LIFESCIENCES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | BH.IMMUN&BIO | ADVANCED ENZYME TECHNOLOGIES | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | 1.00% | 0.38% | -0.08% |
1-Month | 0.10% | 6.50% | 0.53% |
1-Year | 32.88% | 34.20% | 50.88% |
3-Year CAGR | -17.98% | -5.72% | 13.33% |
5-Year CAGR | 32.40% | 17.78% | 21.12% |
* Compound Annual Growth Rate
Here are more details on the BH.IMMUN&BIO share price and the ADVANCED ENZYME TECHNOLOGIES share price.
Moving on to shareholding structures...
The promoters of BH.IMMUN&BIO hold a 59.3% stake in the company. In case of ADVANCED ENZYME TECHNOLOGIES the stake stands at 43.5%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of BH.IMMUN&BIO and the shareholding pattern of ADVANCED ENZYME TECHNOLOGIES.
Finally, a word on dividends...
In the most recent financial year, BH.IMMUN&BIO paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of -0.0%.
ADVANCED ENZYME TECHNOLOGIES paid Rs 5.0, and its dividend payout ratio stood at 53.8%.
You may visit here to review the dividend history of BH.IMMUN&BIO, and the dividend history of ADVANCED ENZYME TECHNOLOGIES.
For a sector overview, read our pharmaceuticals sector report.
After opening the day marginally higher, Indian share markets continued the momentum as the session progressed and ended the day higher.